Trials / Recruiting
RecruitingNCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 508 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AZD0120 | CAR-T Cells |
| DRUG | Daratumumab | Daratumumab |
| DRUG | Carfilzomib | Carfilzomib |
| DRUG | Dexamethasone | Dexamethasone |
| DRUG | Bortezomib | Bortezomib |
| DRUG | Pomalidomide | Pomalidomides |
Timeline
- Start date
- 2026-02-23
- Primary completion
- 2028-08-30
- Completion
- 2030-07-29
- First posted
- 2026-02-06
- Last updated
- 2026-03-12
Locations
108 sites across 14 countries: United States, Australia, Brazil, Canada, France, Germany, Italy, Japan, Norway, Poland, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07391657. Inclusion in this directory is not an endorsement.